Orasure Technologies AI Stock Analysis
Want to see OSUR full AI Analyst Report?
Orasure Technologies (OSUR) AI Stock Analysis
Orasure Technologies
(NASDAQ:OSUR)
The overall score is 45, reflecting a high-risk profile. The primary drag is the company's poor financial performance, marked by significant losses and cash burn, which overshadows a strong balance sheet. While the latest earnings call indicates a potential turnaround with a return to growth, this positive signal is not yet reflected in the financial statements or technical trends, which remain weak. The delayed path to cash flow breakeven is a critical risk factor.
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $249.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 575.72K
- Price to Earnings (P/E)
- -5.2
- Beta (1Y)
- 0.85
- Revenue Growth
- -7.53%
- EPS Growth
- 14.93%
- Country
- US
- Employees
- 500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Orasure Technologies Business Overview & Revenue Model
Company Description
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, E...
How the Company Makes Money
OraSure makes money primarily by selling diagnostic tests and sample collection/collection-device products to customers such as public health agencies, hospitals and clinics, laboratories, distributors, and other healthcare-related organizations. A k...
Orasure Technologies Earnings Call Summary
The call was broadly positive, reflecting a return to growth, strong performance in Diagnostic Products and Sample Management Solutions, gross margin expansion, lower operating spend, a debt-free balance sheet, and confidence in 2027 revenue acceleration. However, the company remains loss-making with negative operating cash flow, delayed cash flow breakeven, uncertain CT/NG regulatory timing, and delayed Ebola contracting catalysts. The highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter, OraSure expects revenue between $30 million and $32 million, representing year-over-year growth of approximately 12% to 20%, with gross margin in Q4 expected to be similar to or slightly below Q3 and OpEx expected to be similar to Q3 overall; full year 2026 revenue is expected between $119.5 million and $121.5 million, implying a full year growth rate between 3.8% and 5.6%, with 4.7% at the midpoint. The company now expects to reach cash flow from operations breakeven in the second half of 2027 and expects full year revenue growth to accelerate in 2027 compared with 2026, with additional insights to be provided on the fourth quarter earnings call; it also expects strong growth on a year-over-year basis in Q4 and expects that Ebola and Colli-Pee will be part of the acceleration of growth referred to for 2027.
Orasure Technologies Financial Statement Overview
Summary
Financial performance is deeply challenged. The income statement shows a dramatic revenue collapse and significant net losses, while cash flow is severely negative, indicating ongoing cash burn. The only mitigating factor is a strong, debt-free balance sheet, but the overall financial health is poor due to unprofitable operations.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 116.23M | 115.02M | 185.83M | 405.47M | 387.48M | 233.67M |
| Gross Profit | 48.71M | 48.20M | 76.23M | 179.42M | 148.44M | 117.60M |
| EBITDA | -40.21M | -56.74M | -6.83M | 77.20M | -139.00K | 2.37M |
| Net Income | -48.51M | -68.73M | -19.50M | 53.66M | -17.13M | -23.00M |
Balance Sheet | ||||||
| Total Assets | 349.47M | 403.17M | 479.66M | 482.85M | 444.18M | 460.99M |
| Cash, Cash Equivalents and Short-Term Investments | 148.24M | 199.28M | 267.76M | 290.41M | 110.85M | 153.04M |
| Total Debt | 11.65M | 13.20M | 14.60M | 13.50M | 12.55M | 12.27M |
| Total Liabilities | 42.33M | 62.34M | 69.32M | 52.17M | 79.75M | 80.46M |
| Stockholders Equity | 307.13M | 340.83M | 410.34M | 430.67M | 364.43M | 380.53M |
Cash Flow | ||||||
| Free Cash Flow | -49.62M | -53.22M | 23.58M | 131.28M | -111.11M | -83.50M |
| Operating Cash Flow | -43.68M | -49.02M | 27.37M | 141.58M | -47.20M | -35.38M |
| Investing Cash Flow | -9.42M | -6.81M | -39.03M | 66.15M | 21.09M | -5.50M |
| Financing Cash Flow | -13.68M | -16.94M | -4.18M | -3.02M | -3.83M | -2.82M |
Orasure Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Neutral. The current price of 3.46 is below the 20-day moving average (MA) of 3.70, below the 50-day MA of 3.74, and below the 200-day MA of 3.57, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 47.94 is Neutral, neither overbought nor oversold. The STOCH value of 68.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksOrasure Technologies Peers Comparison
Overall Rating
UTMD73Outperform
INFU70Outperform
SMTI52Neutral
STXS47Neutral
OSUR45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $202.20M | 21.23 | 8.78% | 1.75% | -9.62% | -5.65% | |
| 70Outperform | $281.67M | 29.89 | 15.77% | ― | 2.40% | 76.01% | |
| 52Neutral | $300.00M | -91.44 | -42.22% | ― | 9.82% | 91.93% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $101.86M | -4.15 | -115.83% | ― | 4.83% | 15.55% | |
| 45Neutral | $249.26M | -5.23 | -15.17% | ― | -7.53% | 14.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OSUR | Orasure | 3.46 | 1.04 | 42.98% | |
| INFU | InfuSystem Holdings, Inc. | 14.35 | 4.84 | 50.89% | |
| STXS | Stereotaxis | 0.94 | -1.42 | -60.08% | |
| UTMD | Utah Medical Products | 69.49 | 15.31 | 28.26% | |
| MBOT | Microbot Medical | 0.68 | -1.24 | -64.58% | |
| SMTI | Sanara MedTech | 32.55 | 12.85 | 65.23% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
